MS
JSPRW icon

Maven Securities’s Japer Therapeutics Warrants JSPRW Stock Holding History

Maven Securities’s Portfolio JSPRW Stock Details JSPRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100,000
Closed -$148K – 1002
2021
Q3 		$148K Hold
100,000
– – ﹤0.01% 977
2021
Q2 		$116K Hold
100,000
– – ﹤0.01% 963
2021
Q1 		$82K Hold
100,000
– – ﹤0.01% 1028
2020
Q4 		$155K Hold
100,000
– – 0.02% 515
2020
Q3 		$118K Hold
100,000
– – 0.01% 574
2020
Q2 		$100K Hold
100,000
– – 0.01% 508
2020
Q1 		$65K Buy
+100,000
New +$78.6K 0.01% 292

Other funds holding JSPRW

HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.21B AUM 169.99% 1-Year Est. Return
ICM
Ionic Capital Management New York $690M AUM 70.34% 1-Year Est. Return
TCM
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
ICMH
Integrity Capital Management (HK) Central, Hong Kong $19.4M AUM
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Maven Securities's JSPRW Position: Q4 2021 in Review

Maven Securities sold out of Japer Therapeutics Warrants (JSPRW) in Q4 2021, closing a stake of 100,000 shares — an estimated $148K sold.

Maven Securities first reported a position in JSPRW in Q1 2020 and held it in 7 quarters. The position peaked at $155K in Q4 2020. 15 funds tracked by Wall St. Rank hold JSPRW as of Q4 2021.

  • Maven Securities reported no remaining Japer Therapeutics Warrants position as of Q4 2021 after selling out during the quarter.
  • Maven Securities sold 100,000 Japer Therapeutics Warrants shares in Q4 2021, an estimated $148K.
  • Maven Securities first reported a position in Japer Therapeutics Warrants in Q1 2020 and held it in 7 quarters.
  • Maven Securities's Japer Therapeutics Warrants position peaked at $155K in Q4 2020.
  • 15 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q4 2021.

Based on Maven Securities's 13F filing for Q4 2021, filed 14 Feb 2022.